Skip to main content
. 2016 Sep 20;5(10):e1226718. doi: 10.1080/2162402X.2016.1226718

Figure 4.

Figure 4.

Effect of in vitro sorafenib treatment on ERK phosphorylation levels and absolute number of EPC. PBMC samples from HCC patients after treatment with sorafenib (A, C) or TACE (B, D) were treated with different concentrations of sorafenib (0–20 μM) in vitro and the number of pERK+ EPC and absolute number of EPC was measured as described in the Materials and Methods section. Each symbol (Inline graphic) represents an individual HCC patient and lines represent mean values for the group.